GlassScriptPhysician profile
Mark Fisher
NPI 1174623227
$2,379.30
in general payments reported to CMS, 2019-2025
12 companies · $638 in 2025
The $638 reported for 2025 was more than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
See the full distribution for Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $214 · 2023: $792 · 2024: $736 · 2025: $638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,165.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Polynovo North America LLC | $1,139.48 | 2022-2025 | Novosorb Btm |
| Access Pro Medical, LLC | $181.76 | 2025 | Matriderm |
| Depuy Synthes Sales INC. | $179.76 | 2024-2025 | Trumatch, Matrixmandible |
| Abbvie INC. | $170.72 | 2023-2025 | |
| Integra Lifesciences Corporation | $147.04 | 2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Kls-Martin L.P. | $146.34 | 2023 | |
| Smith+Nephew, INC. | $128.07 | 2023 | Oasis |
| Baxter Healthcare | $124.02 | 2025 | Artiss |
| Aroa Biosurgery Incorporated | $47.96 | 2024 | |
| Avita Medical Americas, LLC | $44.23 | 2024 | |
| Vericel Corporation | $35.61 | 2023-2025 | Epicel (Cultured Epidermal Autografts), Nexobrid |
| Medline Industries LP | $34.31 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Fisher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.